Uric Acid as a Cause of the Metabolic Syndrome.
Level 5 - mechanism / opinion, no new human data
Narrative review / mechanism-based reasoning synthesizing mechanistic, animal, and pilot human literature.
PubMed 29393133 · doi:10.1159/000484283
What was done
This narrative review summarizes experimental animal models, mechanistic studies, and preliminary human data evaluating whether hyperuricemia acts as a causal driver—rather than merely a downstream marker—of insulin resistance, type 2 diabetes, and metabolic syndrome.
What was found
The abstract reports no numerical data or effect sizes. It reports that hyperuricemia independently predicts incident diabetes and drives fatty liver, dyslipidemia, and insulin resistance in fructose-dependent and fructose-independent animal models. Mechanistically, uric acid impairs insulin-stimulated endothelial nitric oxide release and induces mitochondrial oxidative stress. Human pilot trials suggest uric acid reduction may improve insulin sensitivity, but definitive data are pending.
Why it matters
If uric acid is a causal mediator rather than an innocent bystander in metabolic disease, lowering serum uric acid could offer an accessible therapeutic strategy to prevent type 2 diabetes.
Limits
As a narrative review, it lacks a systematic literature search, standardized risk-of-bias assessment, or pooled meta-analytic estimates. The causal claims rely heavily on animal models and preliminary pilot studies; large-scale randomized human trials confirming clinical efficacy are not presented.
Cited by
- supports Fructose metabolizes into uric acid, and uric acid plays a pivotal role in insulin resistance, inflammation, and non-alcoholic fatty liver disease.